Global Intravenous Immunoglobulins
Market Report
2024
Intravenous Immunoglobulins Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Intravenous Immunoglobulins Market Report 2024.
Global Intravenous Immunoglobulins Market Report 2024 Market Size Split by Product Type (IgG, IgA, IgM, IgD, IgE), by Application (Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AI...
According to Cognitive Market Research, The Intravenous Immunoglobulin Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Asia Pacific region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Intravenous Immunoglobulin Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Product Type |
|
| Market Split by Application |
|
| Market Split by Distribution Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Intravenous Immunoglobulins industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Intravenous Immunoglobulins Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Intravenous Immunoglobulins Market Report Description
Introduction of The Intravenous Immunoglobulin Market
Intravenous immunoglobulin (IVIG) is a concentrate of pooled immunoglobulins derived from 1000 to 100000 healthy donors depending upon the manufacturer. Immunoglobulins play a pivotal role in humoral adaptive immunity; ergo, IVIG reflects a collective exposure of the donor population to their environment and can be expected to contain an antibody repertoire of multiple specificities against a broad spectrum of infectious agents (bacterial, viral, and others), self-antigens and anti-idiotype antibodies.
The growth in the forecast period can be attributed to the rising prevalence of immunodeficiency disorders, increasing prevalence of rheumatoid arthritis, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches and technological innovation, strategic partnership, collaboration, and acquisition are growing the demand for intravenous immunoglobulin market.
Market Dynamics of The Intravenous Immunoglobulin Market
Key Drivers for The Intravenous Immunoglobulin Market
- The rising prevalence of immunodeficiency disorders fuels the intravenous immunoglobulin market.
An increase in the incidence of immunodeficiency illness and a sharp rise in the number of immunodeficiency medicine releases by well-known companies are the main drivers propelling the market's expansion. Through the replacement of insufficient antibodies, infection prevention, enhancement of immunological function, and management of autoimmune symptoms, immunoglobulins play a critical role in the management of immunodeficiency illnesses. By replacing the absent antibodies, intravenous immunoglobulins (IVIG) help to avoid repeated infections. Due to the increasing prevalence of immunodeficiency diseases, the market is anticipated to rise rapidly throughout the projected period.
For instance, as per the article published by BioMed Central Ltd in March 2022, the prevalence of Common Variable Immunodeficiency (CVID) in the same population was approximately 16.6% in the United States, 22.5% in Canada, and 34.2% in Australia in 2021. The high prevalence of CVID and improved diagnosis and awareness have increased the demand for immunoglobulin therapies.
Source:(https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00662-6)
Thus the increasing prevalence of immunodeficiency disorders is driving immunoglobulin market growth, supported by rising medication releases and the critical role of immunoglobulins in managing these disorders.
For instance, as per an April 2020 update by the Centers for Disease Control and Prevention (CDC), there are more than 400 types of primary immunodeficiencies that vary in severity. Thus, these statistics reflect the rising need for immunoglobulins for the treatment of immunodeficiency disorders.
Source:(https://www.cdc.gov/primary-immunodeficiency/about/index.html#:~:text=There%20are%20more%20than%20400,is%20found%20soon%20after%20birth.)
Thus, these statistics project the rising need for immunoglobulin for the treatment of immunodeficiency disorders through intravenous infusion driving the growth of the intravenous immunoglobulin (IVIG) market.
- The increasing prevalence of rheumatoid arthritis disease propels the growth of intravenous immunoglobulin.
The rising prevalence of rheumatoid arthritis (RA) serves as a significant driver for the growth of intravenous immunoglobulin (IVIG) therapy. RA, a chronic autoimmune disorder affecting joints, is characterized by inflammation and tissue damage, leading to pain, swelling, and impaired mobility. IVIG, with its immunomodulatory properties, offers a promising treatment avenue for RA patients who may have failed conventional therapies. Its ability to regulate immune responses and modulate inflammatory pathways makes it a valuable option, especially in cases where conventional disease-modifying anti-rheumatic drugs (DMARDs) are insufficient or contraindicated. As the prevalence of RA continues to rise globally, the demand for effective and alternative treatments like IVIG is expected to increase, thereby propelling the growth of IVIG therapy in the management of rheumatoid arthritis.
For instance, in 2023, according to the Australian Institute of Health and Welfare, rheumatoid arthritis accounted for 2.0% of total disease burden (DALY); 3.6% of non-fatal burden (YLD), and 0.1% of fatal burden (YLL). In 2020–21, an estimated $966.1 million of expenditure in the Australian health system was for rheumatoid arthritis, representing 0.6% of total health system expenditure and 6.6% of expenditure for all musculoskeletal conditions. Within the musculoskeletal conditions disease group, rheumatoid arthritis accounted for 15.7% of total burden (DALY); 15.7% of non-fatal burden (YLD); and 15.5% of fatal burden (YLL) (AIHW 2023a).
Source:(https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/rheumatoid-arthritis)
For instance, in July 2022, according to the National Rheumatoid Arthritis Society (NRAS), a UK-based non-profit organization, it was estimated that more than 450,000 people in the UK have rheumatoid arthritis. The most common age for people to develop RA is between 40 and 60, or a bit older for men.
Source:(https://nras.org.uk/resource/what-is-ra/)
For instance, in a 2021 investigation according to American Pharma Specialty Care, researchers observed the potent anti-inflammatory action of IVIG in mice, suggesting the potential role of IVIG for rheumatoid arthritis in humans
Source:(https://ameripharmaspecialty.com/ivig-for-rheumatoid-arthritis-does-it-really-work/)
Therefore, the increasing prevalence of rheumatoid arthritis is creating the need for immunoglobulin for treatment of rheumatoid arthritis through intravenous infusion driving the growth of the intravenous immunoglobulin (IVIG) market.
Restraint Factor for The Intravenous Immunoglobulin Market
-
The high cost of intravenous immunoglobulin therapy and its associated side effects restrain the growth of the intravenous immunoglobulin market
Demand for intravenous immunoglobulin treatments is severely constrained by their high cost. These treatments have higher production costs because they need intricate manufacturing procedures and exacting quality standards. Because of this, it is difficult for patients, healthcare professionals, and healthcare systems to pay and obtain these necessary therapies. Intravenous immunoglobulin treatments are not widely used because of the cost aspect, especially in areas with tight healthcare budgets and resources.
Furthermore, by affecting patient trust and adherence, the possibility of side effects and unpleasant responses limits market demand. Adverse effects from intravenous immunoglobulin therapy can range in severity from minor responses to serious problems. Fears regarding safety and possible side effects would discourage doctors and patients from choosing these treatments, which would impede the intravenous immunoglobulin products' general expansion and adoption in the medical community. It is imperative to tackle these obstacles to guarantee increased accessibility and long-term market expansion.
For instance, in January 2022 patients require regular infusions, which affects their quality of life. The financial burden is also significant: The treatment costs between $30,000 and $90,000 in the U.S. Consequently, the elevated treatment expenses are expected to act as a barrier to market demand.
Source:(https://www.research.chop.edu/cornerstone-blog/is-lifelong-immunoglobulin-replacement-therapy-cost-effective-to-treat-agammaglobulinemia#:~:text=The%20therapy%20reduces%20the%20number,and%20%2490%2C000%20in%20the%20U.S.)
For instance, according to a 2023 article published by AmeriPharma Specialty Care, a single IVIG infusion can cost anywhere from $100 to over $350 or more per gram. n average, the reported cost for IVIG treatment in the US is approximately $9,720, and if patients undergo 4 to 5 infusions per month, then it would cost them around $41,796 per month. Even though IVIG infusions offer hope and an improved quality of life, the financial aspect can be daunting for many patients and their families.
Source:(https://ameripharmaspecialty.com/cost-of-ivig-treatment/)
However, the high cost and potential side effects of intravenous immunoglobulin therapy pose challenges to market demand, hindering accessibility and adoption within the medical community.
How did COVID-19 impact the Intravenous Immunoglobulin Market
The COVID-19 epidemic has had three primary effects on the economies of different parts of the world: firstly, it has directly impacted supply and demand; second, it has disrupted distribution networks; and third, it has had a financial impact on businesses and financial markets. Several nations, worldwide are having issues with the distribution and delivery of medical supplies. However, because more research and development is being done on intravenous immunoglobulins (IVIG) for the treatment of COVID-19, the impact of the coronavirus (COVID-19) pandemic is anticipated to propel the growth of the intravenous immunoglobulin market.
For instance, according to an October 2020 published article titled, 'The uSAGE of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial', the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to enhance the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Hence, the global market is likely to witness strong growth during the pandemic.
Source:(https://pubmed.ncbi.nlm.nih.gov/33087047/)
• For instance, according to the article published in Respiration journal, in January 2021, early IVIG administration was associated with reduced ventilator use, hospital and intensive care unit length of stay in a retrospective study conducted in the U.S. and Germany including patients from three hospitals. In a retrospective study of 58 cases with severe or critical illness due to COVID-19, early administration of IVIG was associated with reduced ventilator use, reduced hospital and intensive care unit length of stay, and improved 28-day mortality.
Source:(https://karger.com/res/article/99/12/1087/308146/Intravenous-Immunoglobulin-for-the-Treatment-of)
Opportunities for The Intravenous Immunoglobulin Market
- Advancement in human plasma-derived IVIG products may represent a significant opportunity to drive the intravenous immunoglobulin market.
Advancements in human plasma-derived IVIG (intravenous immunoglobulin) products offer a significant opportunity to propel the intravenous immunoglobulin market forward due to several key factors. Improvements in purification processes and technology enhance product quality and safety, reducing the risk of adverse reactions and increasing patient acceptance. Innovations in manufacturing enable higher yields and more efficient production, potentially alleviating supply constraints and meeting growing demand. Additionally, refined formulations and tailored product profiles may lead to enhanced efficacy for treating a broader range of autoimmune and inflammatory conditions, expanding the market reach and utility of IVIG therapy. Moreover, these advancements position plasma-derived IVIG products as a cornerstone in the management of various chronic inflammatory diseases and immune-mediated disorders, driving market growth and improving patient outcomes.
For instance, in January 2024 OSAKA, Japan and CAMBRIDGE, Massachusetts, January 29, 2024 – Takeda announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy derived from human plasma to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
Source:(https://www.takeda.com/en-us/newsroom/news-releases/2024/takedas-gammagard-liquid-approved-for-adults-with-cidp-in-united-states#:~:text=OSAKA%2C%20Japan%20and%20CAMBRIDGE%2C%20Massachusetts,to%20improve%20neuromuscular%20disability%20and)
For instance, in June 2021, Octapharma, a Swiss pharmaceutical company, announced that its new product ‘Octagam 10%’, a human plasma-derived intravenous immunoglobulin (IVIg) was granted approval by the European Union (EU) as immunotherapy for adults with dermatomyositis, and national approval by Germany for the same indication. Octagam 10% is the first therapy to be approved for dermatomyositis in the EU and indicated for adults with active dermatomyositis treated with immunosuppressive drugs. This innovative product will help improve the lives of people with dermatomyositis, which is a rare, idiopathic autoimmune disorder.
Source:(https://www.octapharma.com/news/press-release/2021/approval-of-octagam-10percent-for-adults-with-dermatomyositis)
Thus, advancements in human plasma-derived IVIG products enhance safety, increase efficiency, and improve efficacy, driving market growth and expanding treatment options for chronic inflammatory immune-mediated disorders.
We have various report editions of Intravenous Immunoglobulins Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Intravenous Immunoglobulin Market
The major key players operating in the intravenous immunoglobulin market are involved in research and development to develop new immunoglobulin drugs which will contribute to further growth in the intravenous immunoglobulin market. To increase their worldwide presence, market players are also engaging in a range of strategic initiatives. Notable advancements in the industry include the introduction of new product types, contracts, mergers and acquisitions, increased investment, and cooperation with other institutions.
For instance, in March 2021, Grifols SA, a Spanish pharmaceutical and chemical manufacturer acquired GigaGen Inc for $115 million. The acquisition was completed in two stages; in the first stage, Grifols bought a 44% stake for $35 million and in the second stage, it bought the remaining 56% share for $80 million. The acquisition is in line with Grifols’ R+D+I (research, development, and innovation) strategy to boost innovation and perform research that compliments its core operations. GigaGen is a US-based biotechnology company specializing in the development and discovery of recombinant biotherapeutic medicines.
Source:(https://www.prnewswire.com/news-releases/grifols-reinforces-its-innovation-strategy-after-completing-the-acquisition-of-gigagen-to-boost-a-novel-method-to-generate-a-wide-range-of-immunoglobulins-301243039.html)
Top Companies Market Share in Intravenous Immunoglobulins Industry: (In no particular order of Rank)
- Takeda Pharmaceutical Company Limited
- Grifols SA
- CSL Behring
- ADMA Biologics
- Octapharma AG
- Baxter International Inc
- LFB Biotechnologies
- China Biologics Products Inc.
- Kedrion Biopharma
- Intas Pharmaceuticals
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of The Intravenous Immunoglobulin Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North America region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. The major factors propelling the market's growth in the country are a developed and well-structured healthcare system; a growing focus on research and development; and the strong presence of market players. The United States is expected to hold a major share of the market in North America.
Additionally, the growing burden of target diseases such as primary immunodeficiency diseases in the region is expected to boost the market's growth.
For instance, according to the National Institute of Allergy and Infectious Diseases, in 2020, more than 400 types of varied PIDs were diagnosed in the United States, accounting for more than 500,000 American populations affected by PIDs. Furthermore, it is anticipated that the region's intravenous immunoglobulin market would increase due to a rise in R&D efforts and a quick approval process for new products.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231820/)
For instance, in August 2021, Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company based in the United States, reported the start of a Phase III clinical trial to evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus (COVID-19) who are at high risk of progression to severe disease.
Source:(https://www.emergentbiosolutions.com/press/news-release-details-emergent-biosolutions-covid-19-human-immune-globulin-product-0/)
Additionally, in February 2021, Pfizer received the United States Food and Drug Administration approval for the supplemental Biologics License Application (sBLA), which was submitted for PANZYGA, an intravenous immunoglobulin (IVIg) to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Source:(https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-panzygar-treatment-adults-chronic)
Thus, the market is anticipated to witness significant growth during the forecast period due to the above-given factors.
Which Region Is Expanding at The Fastest CAGR?
The Asia Pacific is projected to grow at a faster rate with a CAGR of XX% during the forecast period between 2024 and 2031. The Asia-Pacific. market for intravenous immunoglobulin is projected to be the fastest-growing region with a CAGR of XX% during the forecast period 2024-2031. In Asia-Pacific, the market for intravenous immunoglobulins is experiencing dynamic interventions driven by increased autoimmune disease prevalence and healthcare awareness. There is a noticeable increase in therapeutic applications in the area, especially in the fields of neurology and hematology. Technological developments and collaborations for localized production improve access to intravenous immunoglobulin therapy. Steady expansion in the Asia-Pacific market is attributed to growing government initiatives for vaccination programs and the development of healthcare infrastructure.
For instance, in September 2023, Biotest received approval for its intravenous immunoglobulin Yimmugo in the United Kingdom for the treatment of patients with congenital and acquired immunodeficiency.
Source:(https://www.eqs-news.com/news/corporate/biotest-ag-biotest-receives-approval-for-innovative-immunoglobulin-yimmugo-in-the-uk/1903009#:~:text=Biotest%20AG%20announced%20today%20that,approvals%20in%20Germany%20and%20Austria.)
For instance, in January 2022, argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). VYVGART is the first and only neonatal Fc receptor (FcRn) blocker approved in Japan.
Source:(https://www.argenx.com/news/argenx-announces-vyvgarttm-approval-japan-treatment-generalized-myasthenia-gravis)
The current report Scope analyzes Intravenous Immunoglobulins Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Intravenous Immunoglobulins Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Intravenous Immunoglobulins Market Analysis
Global Intravenous Immunoglobulins Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Intravenous Immunoglobulins Industry growth. Intravenous Immunoglobulins market has been segmented with the help of its Product Type, Application Distribution Channel , and others. Intravenous Immunoglobulins market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Intravenous Immunoglobulin Market
Product Type Segment Analysis
The IgG segment dominated the market, constituting the largest share. The primary reason for this is the extraordinary adaptability of IgG, which covers a wide range of immune system tasks. Its essential functions include immune response regulation, phagocytosis facilitation, and pathogen neutralization, treating primary and secondary immunodeficiency, autoimmune diseases, and infectious diseases. IgG offers long-lasting immunity and is highly effective in managing various medical conditions. IgG is a very attractive option for the treatment of a variety of illnesses because of its versatility.
For instance, in January 2022, Argenx SE, a global immunology company, announced the approval of VYVGART by Japan's Ministry of Health, Labor and Welfare (MHLW). VYVGART, administered through an intravenous infusion (efgartigimod alfa), is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who have not responded adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).
Source:(https://www.argenx.com/news/argenx-announces-approval-vyvgart-efgartigimod-alfa-japan-adults-primary-immune)
Thus, a growing number of product approvals would encourage market growth. The advancement of government efforts supporting intravenous drug administration is another factor driving the growth of the worldwide market.
Intravenous Immunoglobulins Market Share (%) by Product Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Intravenous Immunoglobulins Industry. Request a Free Sample PDF!
Application Segment Analysis
The immunodeficiency segment dominated the global intravenous immunoglobulin market due to the growing incidence of primary and acquired immunodeficiency diseases. To treat PID and AIDS, intravenous antibiotics are used to eradicate the infections. When it comes to immunodeficiency diseases, IVIG replacement therapy is the best available alternative. Corticosteroids, plasmapheresis, and immunosuppressive drugs are commonly used to treat chronic inflammatory demyelinating polyneuropathy, which accounts for the second-largest percentage of cases. In place of these therapies, IVIG offers a durable and efficient substitute. The sector's growth is aided by the concomitant benefits, which include safety, little invasiveness, and intuitiveness. The rising global incidence of primary immunodeficiency diseases (PID) has led to hypogammaglobulinemia having the third-largest revenue share. Patients with lymphoproliferative disease (LPDs) are most likely to have this persistent immune deficit.
For instance, in June 2022, Amgen received United States Food and Drug Administration (FDA) approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Source:(https://www.amgen.com/newsroom/press-releases/2022/06/fda-approves-riabni-rituximabarrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis)
For instance, as per the article published by BioMed Central Ltd in March 2022, the prevalence of Common Variable Immunodeficiency (CVID) in the same population was approximately 16.6% in the United States, 22.5% in Canada, and 34.2% in Australia in 2021. The high prevalence of CVID and improved diagnosis and awareness have increased the demand for immunoglobulin therapies.
Source:(https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00662-6)
For instance, as per an April 2020 update by the Centers for Disease Control and Prevention (CDC), there are more than 400 types of primary immunodeficiencies that vary in severity. Thus, these statistics reflect the rising need for immunoglobulins for the treatment of immunodeficiency disorders.
Source:(https://www.cdc.gov/primary-immunodeficiency/about/index.html#:~:text=There%20are%20more%20than%20400,is%20found%20soon%20after%20birth.)
Thus the increasing prevalence of immunodeficiency disorders is driving immunoglobulin market growth, supported by rising medication releases and the critical role of immunoglobulins in managing these disorders.
Intravenous Immunoglobulins Market Share (%) by Application in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Intravenous Immunoglobulins market report 2024 Edition by contacting our team.
Intravenous Immunoglobulins Distribution Channel Segment Analysis
Distribution Channel Segment Analysis
The hospital pharmacy segment holds the largest market share. Hospital pharmacies are committed to providing care that is focused on the patient. IVIG treatment frequently necessitates meticulous coordination, monitoring, and dosage. Hospital pharmacists ensure that patients receive the proper dosage and treatment regimens that are customized for their individual needs. Hospital pharmacists are also highly skilled experts in drug interactions, patient safety, and medication management. Hospital pharmacist assistance is essential to ensuring safe and successful treatment of IVIG therapy since it requires complicated dose and administration issues.
For instance, data from the American Hospital Association (AHA) in 2022 reveals that the U.S. had a total of 6,120 hospitals in the United States with a cumulative 3.4 million hospital admissions. Therefore, the rising number of patients requesting hospitalization services is expected to support this market's growth.
Source:(https://www.aha.org/statistics/fast-facts-us-hospitals)
For instance, in 2021–22, there were 10,000 hospitalizations with a principal diagnosis of rheumatoid arthritis (39 hospitalizations per 100,000 population).
Source:(https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/rheumatoid-arthritis)
- Hospital Pharmacy
- Specialty Pharmacy
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
I am a dedicated and detail-oriented research analyst, committed to unraveling the stories hidden within data. With a solid foundation in market research & analysis, I thrive in the dynamic realm of research, where every dataset presents an opportunity for discovery. My passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.
I am committed to continuous professional development, regularly participating in workshops, attending conferences, and staying attuned to emerging trends in research methodologies to maintain the highest standards in my work. I played a vital role in conducting market research and competitive analysis. I have a proven track record of synthesizing diverse datasets, employing statistical models, and presenting comprehensive insights. My collaborative approach with cross-functional teams facilitated effective communication of findings, fostering a culture of data-driven decision-making within the organization.
Author's Conclusion
With the help of the above study about the Intravenous Immunoglobulin Market, it can be concluded that the market for intravenous immunoglobulin worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Latest News about Intravenous Immunoglobulins Market
In January 2023, Eisai Co., Ltd., and Biogen Inc. announced a License Application to the US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status.
Source:(https://investors.biogen.com/news-releases/news-release-details/eisai-initiates-rolling-biologics-license-application-us-fda)
In June 2022- Baxter issued an urgent Medical Device Correction to Reinforce Important Safety Information Regarding the Possible Risk of Oxygen Desaturation While Using a Volara Device in Line with Ventilator in a Home Care Environment.
Source:(https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-issues-urgent-medical-device-correction-reinforce-important-safety-information-regarding#:~:text=announced%20today%20it%20has%20issued,barotrauma)%20in%20the%20home%20care)
In June 2022- Biotest AG: Biotest achieves an essential milestone in the Phase III study in acquired fibrinogen deficiency.
Source:(https://www.biotest.com/de/en/r_d/pipeline/fibrinogen.cfm)
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Intravenous Immunoglobulins Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Product Type | IgG, IgA, IgM, IgD, IgE |
| Application | Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Distribution Channel | Hospital Pharmacy, Specialty Pharmacy |
| List of Competitors | Takeda Pharmaceutical Company Limited, Grifols SA, CSL Behring, ADMA Biologics, Octapharma AG, Baxter International Inc, LFB Biotechnologies, China Biologics Products Inc., Kedrion Biopharma, Intas Pharmaceuticals |
This chapter will help you gain GLOBAL Market Analysis of Intravenous Immunoglobulins. Further deep in this chapter, you will be able to review Global Intravenous Immunoglobulins Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Intravenous Immunoglobulins Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Intravenous Immunoglobulins Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Intravenous Immunoglobulins Revenue Market Size By Region
-
-
1.3 Global Intravenous Immunoglobulins Market Size By Product Type 2019 -2031
-
1.3.1 IgG Market Size
-
1.3.2 IgA Market Size
-
1.3.3 IgM Market Size
-
1.3.4 IgD Market Size
-
1.3.5 IgE Market Size
-
-
1.4 Global Intravenous Immunoglobulins Market Size By Application 2019 -2031
-
1.4.1 Hypogammaglobulinemia Market Size
-
1.4.2 CIDP Market Size
-
1.4.3 Immunodeficiency Diseases Market Size
-
1.4.4 Congenital AIDS Market Size
-
1.4.5 Chronic Lymphocytic Leukemia Market Size
-
1.4.6 Myasthenia Gravis Market Size
-
1.4.7 Multifocal Motor Neuropathy Market Size
-
1.4.8 ITP Market Size
-
1.4.9 Kawasaki Disease Market Size
-
1.4.10 Guillain-Barre Syndrome Market Size
-
-
1.5 Global Intravenous Immunoglobulins Market Size By Distribution Channel 2019 -2031
-
1.5.1 Hospital Pharmacy Market Size
-
1.5.2 Specialty Pharmacy Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Product Type
-
1.7.3 Global Market Revenue Split By Application
-
1.7.4 Global Market Revenue Split By Distribution Channel
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Intravenous Immunoglobulins Market Size 2019 - 2031
-
2.1.1 North America Intravenous Immunoglobulins Market Size By Country 2019 - 2031
-
2.1.2 North America Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
2.1.2.1 North America IgG Market Size
-
2.1.2.2 North America IgA Market Size
-
2.1.2.3 North America IgM Market Size
-
2.1.2.4 North America IgD Market Size
-
2.1.2.5 North America IgE Market Size
-
-
2.1.3 North America Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
2.1.3.1 North America Hypogammaglobulinemia Market Size
-
2.1.3.2 North America CIDP Market Size
-
2.1.3.3 North America Immunodeficiency Diseases Market Size
-
2.1.3.4 North America Congenital AIDS Market Size
-
2.1.3.5 North America Chronic Lymphocytic Leukemia Market Size
-
2.1.3.6 North America Myasthenia Gravis Market Size
-
2.1.3.7 North America Multifocal Motor Neuropathy Market Size
-
2.1.3.8 North America ITP Market Size
-
2.1.3.9 North America Kawasaki Disease Market Size
-
2.1.3.10 North America Guillain-Barre Syndrome Market Size
-
-
2.1.4 North America Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
2.1.4.1 North America Hospital Pharmacy Market Size
-
2.1.4.2 North America Specialty Pharmacy Market Size
-
-
-
2.2 Add-Ons: Customize the Report Edition
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
-
2.2.1 North America Company Market Share 2019 till 2023
-
2.2.2 Qualitative Analysis for North America Market
Qualitative Analysis for the North America Market: North America Intravenous Immunoglobulins Market Trends North America Intravenous Immunoglobulins Technological Road Map North America Intravenous Immunoglobulins Market Drivers North America Intravenous Immunoglobulins Market Restraints North America Intravenous Immunoglobulins Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
-
-
2.3 Executive Summary North America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
-
2.3.1 North America Market Summary 2019 vs 2024 vs 2031
-
2.3.2 North America Market Revenue Split By Product Type
-
2.3.3 North America Market Revenue Split By Application
-
2.3.4 North America Market Revenue Split By Distribution Channel
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Intravenous Immunoglobulins Market Size 2019 - 2031
-
3.1.1 Europe Intravenous Immunoglobulins Market Size By Country 2019 - 2031
-
3.1.2 Europe Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
3.1.2.1 Europe IgG Market Size
-
3.1.2.2 Europe IgA Market Size
-
3.1.2.3 Europe IgM Market Size
-
3.1.2.4 Europe IgD Market Size
-
3.1.2.5 Europe IgE Market Size
-
-
3.1.3 Europe Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
3.1.3.1 Europe Hypogammaglobulinemia Market Size
-
3.1.3.2 Europe CIDP Market Size
-
3.1.3.3 Europe Immunodeficiency Diseases Market Size
-
3.1.3.4 Europe Congenital AIDS Market Size
-
3.1.3.5 Europe Chronic Lymphocytic Leukemia Market Size
-
3.1.3.6 Europe Myasthenia Gravis Market Size
-
3.1.3.7 Europe Multifocal Motor Neuropathy Market Size
-
3.1.3.8 Europe ITP Market Size
-
3.1.3.9 Europe Kawasaki Disease Market Size
-
3.1.3.10 Europe Guillain-Barre Syndrome Market Size
-
-
3.1.4 Europe Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
3.1.4.1 Europe Hospital Pharmacy Market Size
-
3.1.4.2 Europe Specialty Pharmacy Market Size
-
-
-
3.2 Add-Ons: Customize the Report Edition
-
3.2.1 Europe Company Market Share 2019 till 2023
-
3.2.2 Qualitative Analysis for Europe Market
-
-
3.3 Executive Summary Europe Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
-
3.3.1 Europe Revenue Market Summary 2019 vs 2024 vs 2031
-
3.3.2 Europe Market Revenue Split By Product Type
-
3.3.3 Europe Market Revenue Split By Application
-
3.3.4 Europe Market Revenue Split By Distribution Channel
-
Chapter 4 Asia-Pacific Market Analysis
-
4.1 Asia Pacific Intravenous Immunoglobulins Market Size 2019 - 2031
-
4.1.1 Asia Pacific Intravenous Immunoglobulins Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
4.1.2.1 Asia Pacific IgG Market Size
-
4.1.2.2 Asia Pacific IgA Market Size
-
4.1.2.3 Asia Pacific IgM Market Size
-
4.1.2.4 Asia Pacific IgD Market Size
-
4.1.2.5 Asia Pacific IgE Market Size
-
-
4.1.3 Asia Pacific Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
4.1.3.1 Asia Pacific Hypogammaglobulinemia Market Size
-
4.1.3.2 Asia Pacific CIDP Market Size
-
4.1.3.3 Asia Pacific Immunodeficiency Diseases Market Size
-
4.1.3.4 Asia Pacific Congenital AIDS Market Size
-
4.1.3.5 Asia Pacific Chronic Lymphocytic Leukemia Market Size
-
4.1.3.6 Asia Pacific Myasthenia Gravis Market Size
-
4.1.3.7 Asia Pacific Multifocal Motor Neuropathy Market Size
-
4.1.3.8 Asia Pacific ITP Market Size
-
4.1.3.9 Asia Pacific Kawasaki Disease Market Size
-
4.1.3.10 Asia Pacific Guillain-Barre Syndrome Market Size
-
-
4.1.4 Asia Pacific Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
4.1.4.1 Asia Pacific Hospital Pharmacy Market Size
-
4.1.4.2 Asia Pacific Specialty Pharmacy Market Size
-
-
-
4.2 Add-Ons: Customize the Report Edition
-
4.2.1 Asia Pacific Company Market Share 2019 till 2023
-
4.2.2 Qualitative Analysis for Asia Pacific Market
-
-
4.3 Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
-
4.3.1 Asia Pacific Market Summary 2019 vs 2024 vs 2031
-
4.3.2 Asia Pacific Market Revenue Split By Product Type
-
4.3.3 Asia Pacific Market Revenue Split By Application
-
4.3.4 Asia Pacific Market Revenue Split By Distribution Channel
-
Chapter 5 South America Market Analysis
-
5.1 South America Intravenous Immunoglobulins Market Size 2019 - 2031
-
5.1.1 South America Intravenous Immunoglobulins Revenue Market Size By Country 2019 - 2031
-
5.1.2 South America Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
5.1.2.1 South America IgG Market Size
-
5.1.2.2 South America IgA Market Size
-
5.1.2.3 South America IgM Market Size
-
5.1.2.4 South America IgD Market Size
-
5.1.2.5 South America IgE Market Size
-
-
5.1.3 South America Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
5.1.3.1 South America Hypogammaglobulinemia Market Size
-
5.1.3.2 South America CIDP Market Size
-
5.1.3.3 South America Immunodeficiency Diseases Market Size
-
5.1.3.4 South America Congenital AIDS Market Size
-
5.1.3.5 South America Chronic Lymphocytic Leukemia Market Size
-
5.1.3.6 South America Myasthenia Gravis Market Size
-
5.1.3.7 South America Multifocal Motor Neuropathy Market Size
-
5.1.3.8 South America ITP Market Size
-
5.1.3.9 South America Kawasaki Disease Market Size
-
5.1.3.10 South America Guillain-Barre Syndrome Market Size
-
-
5.1.4 South America Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
5.1.4.1 South America Hospital Pharmacy Market Size
-
5.1.4.2 South America Specialty Pharmacy Market Size
-
-
-
5.2 Add-Ons: Customize the Report Edition
-
5.2.1 South America Company Market Share 2019 till 2023
-
5.2.2 Qualitative Analysis for South America Market
-
-
5.3 Executive Summary South America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
-
5.3.1 South America Market Summary 2019 vs 2024 vs 2031
-
5.3.2 South America Market Revenue Split By Product Type
-
5.3.3 South America Market Revenue Split By Application
-
5.3.4 South America Market Revenue Split By Distribution Channel
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Intravenous Immunoglobulins Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Intravenous Immunoglobulins Revenue Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
6.1.2.1 Middle East and Africa IgG Market Size
-
6.1.2.2 Middle East and Africa IgA Market Size
-
6.1.2.3 Middle East and Africa IgM Market Size
-
6.1.2.4 Middle East and Africa IgD Market Size
-
6.1.2.5 Middle East and Africa IgE Market Size
-
-
6.1.3 Middle East and Africa Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
6.1.3.1 Middle East and Africa Hypogammaglobulinemia Market Size
-
6.1.3.2 Middle East and Africa CIDP Market Size
-
6.1.3.3 Middle East and Africa Immunodeficiency Diseases Market Size
-
6.1.3.4 Middle East and Africa Congenital AIDS Market Size
-
6.1.3.5 Middle East and Africa Chronic Lymphocytic Leukemia Market Size
-
6.1.3.6 Middle East and Africa Myasthenia Gravis Market Size
-
6.1.3.7 Middle East and Africa Multifocal Motor Neuropathy Market Size
-
6.1.3.8 Middle East and Africa ITP Market Size
-
6.1.3.9 Middle East and Africa Kawasaki Disease Market Size
-
6.1.3.10 Middle East and Africa Guillain-Barre Syndrome Market Size
-
-
6.1.4 Middle East and Africa Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
6.1.4.1 Middle East and Africa Hospital Pharmacy Market Size
-
6.1.4.2 Middle East and Africa Specialty Pharmacy Market Size
-
-
-
6.2 Add-Ons: Customize the Report Edition
-
6.2.1 Middle East and Africa Company Market Share 2019 till 2023
-
6.2.2 Qualitative Analysis for Middle East and Africa Market
-
-
6.3 Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
-
6.3.1 Middle East and Africa Market Summary 2019 vs 2024 vs 2031
-
6.3.2 Middle East and Africa Market Revenue Split By Product Type
-
6.3.3 Middle East and Africa Market Revenue Split By Application
-
6.3.4 Middle East and Africa Market Revenue Split By Distribution Channel
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Intravenous Immunoglobulins Market Size by Product Type 2019 -2031
-
7.1.2 Country 1Intravenous Immunoglobulins Market Size by Application 2019 -2031
-
7.1.3 Country 1Intravenous Immunoglobulins Market Size by Distribution Channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Intravenous Immunoglobulins Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Takeda Pharmaceutical Company Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Grifols SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 CSL Behring
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 ADMA Biologics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Octapharma AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Baxter International Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 LFB Biotechnologies
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 China Biologics Products Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Kedrion Biopharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Intas Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Product Type Analysis 2019 -2031, will provide market size split by Product Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Product Type Analysis 2019 -2031
-
10.1 IgG
-
10.1.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by IgG 2019 -2031
-
-
10.2 IgA
-
10.2.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by IgA 2019 -2031
-
-
10.3 IgM
-
10.3.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by IgM 2019 -2031
-
-
10.4 IgD
-
10.4.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by IgD 2019 -2031
-
-
10.5 IgE
-
10.5.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by IgE 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
-
11.1 Hypogammaglobulinemia
-
11.1.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Hypogammaglobulinemia 2019 - 2031
-
-
11.2 CIDP
-
11.2.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by CIDP 2019 - 2031
-
-
11.3 Immunodeficiency Diseases
-
11.3.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Immunodeficiency Diseases 2019 - 2031
-
-
11.4 Congenital AIDS
-
11.4.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Congenital AIDS 2019 - 2031
-
-
11.5 Chronic Lymphocytic Leukemia
-
11.5.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Chronic Lymphocytic Leukemia 2019 - 2031
-
-
11.6 Myasthenia Gravis
-
11.6.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Myasthenia Gravis 2019 - 2031
-
-
11.7 Multifocal Motor Neuropathy
-
11.7.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Multifocal Motor Neuropathy 2019 - 2031
-
-
11.8 ITP
-
11.8.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by ITP 2019 - 2031
-
-
11.9 Kawasaki Disease
-
11.9.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Kawasaki Disease 2019 - 2031
-
-
11.10 Guillain-Barre Syndrome
-
11.10.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Guillain-Barre Syndrome 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Analysis 2019 -2031
-
12.1 Hospital Pharmacy
-
12.1.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Hospital Pharmacy 2019 -2031
-
-
12.2 Specialty Pharmacy
-
12.2.1 Global Intravenous Immunoglobulins Revenue Market Size and Share by Specialty Pharmacy 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Intravenous Immunoglobulins market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Intravenous Immunoglobulins Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Intravenous Immunoglobulins Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Intravenous Immunoglobulins Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Intravenous Immunoglobulins Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Intravenous Immunoglobulins Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Intravenous Immunoglobulins Market
Key Questions Answered By Intravenous Immunoglobulins Market Report 2024
| Why IgG have a significant impact on Intravenous Immunoglobulins market? |
| What are the key factors affecting the IgG and IgA of Intravenous Immunoglobulins Market? |
| What is the CAGR/Growth Rate of Hypogammaglobulinemia during the forecast period? |
| By type, which segment accounted for largest share of the global Intravenous Immunoglobulins Market? |
| Which region is expected to dominate the global Intravenous Immunoglobulins Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
